Lunai Bioworks Inc. (RENB) Research

Lunai Bioworks, Inc. functions as a pre-clinical stage biotechnology enterprise, concentrating its efforts on pioneering genetically modified cell and immunotherapeutic platforms. These advanced technologies are aimed at providing treatments for a range of infectious diseases and oncological conditions. The company's development pipeline features several candidates, specifically ENOB-HV-01, ENOB-HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. Founded on January 18, 2011, by Rene Sindlev and Serhat Gumrukcu, Lunai Bioworks maintains its corporate base in Los Angeles, California.

Market snapshot

Symbol
RENB
Price
$1.42
Day change
0.00%
Market cap
$17.1M
P/E ratio
-0.09x
52-week range
1.1208-21
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Allakos Inc. (ALLK)
  • Angion Biomedica Corp. (ANGN)
  • Freeline Therapeutics Holdings plc (FRLN)
  • Grace Therapeutics, Inc. (GRCE)
  • Opus Genetics, Inc. (IRD)
  • LianBio (LIANY)
  • Marinus Pharmaceuticals, Inc. (MRNS)
  • Oruka Therapeutics, Inc. (ORKA)

Recent insider activity

  • William Anderson Wittekind — J-Other (350000 shares) on 2025-03-10
  • van Tilburg Maurice — A-Award (1000000 shares) on 2025-01-21
  • van Tilburg Maurice — A-Award (250000 shares) on 2025-01-21
  • Fuentes Nathen — A-Award (250000 shares) on 2025-01-21
  • Fuentes Nathen — trade (0 shares) on 2025-01-06

Open Lunai Bioworks Inc. (RENB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.